Loading
Trials recruiting now, the landmark trials, the key papers and what they mean, the latest literature, and the milestones year by year.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Pembrolizumab with gemcitabine-cisplatin is an approved first-line option for advanced biliary tract cancer alongside durvalumab-based therapy.
Durvalumab with gemcitabine-cisplatin is a first-line standard for advanced biliary tract cancer, with pembrolizumab (KEYNOTE-966) as the alternative.
FGFR2 fusion testing is standard in intrahepatic cholangiocarcinoma, and pemigatinib (with futibatinib) is the second-line targeted option for fusion-positive disease.
Adjuvant capecitabine is the standard after resection of intrahepatic and extrahepatic cholangiocarcinoma and gallbladder cancer, endorsed by ASCO and ESMO guidelines.
The clearest early head-to-head of the three biliary sites on one platform: for gallbladder cancer it made HER2 the target to test for and showed that IDH and FGFR inhibitors would rarely apply.
Query for this cancer: (TITLE:"Intrahepatic cholangiocarcinoma" OR ABSTRACT:"Intrahepatic cholangiocarcinoma" OR TITLE:"iCCA" OR ABSTRACT:"iCCA" OR TITLE:"Intrahepatic bile duct cancer" OR ABSTRACT:"Intrahepatic bile duct cancer" OR TITLE:"Peripheral cholangiocarcinoma" OR ABSTRACT:"Peripheral cholangiocarcinoma" OR TITLE:"Mass-forming cholangiocarcinoma" OR ABSTRACT:"Mass-forming cholangiocarcinoma") AND (treatment OR therapy OR trial OR survival OR diagnosis). Results are unfiltered search hits about Intrahepatic cholangiocarcinoma, not a curated reading list.